Fang Zhang

Dr. Zhang brings 20 years of experience in drug discovery in both pharmaceutical and biotech settings. Prior to joining ShouTi, Dr. Zhang served as Chief Executive Officer of Shanghai Tuojie Biomedical Technology and Vice President at Hengrui Medicine, where she built up the Tuojie organization and therapeutic pipeline. Before Tuojie, Dr. Zhang held various leadership positions at Novo Nordisk, including Vice President at Novo Nordisk Research Centre China and Senior Director at Novo Nordisk Research Centre Oxford in the UK, where she led multiple functions including biology, bioanalysis, pharmacology, and discovery technology. Before Novo Nordisk, Dr. Zhang held research positions in the U.S. at Eli Lilly and Company, Metabolex (now CymaBay Therapeutics), and DNA Sciences. Dr. Zhang has a long-term research interest and passion in drug discovery for cardio-metabolic diseases with patents and scientific publications in this field. Dr. Zhang obtained a Ph.D. in oncological sciences from the University of Utah and a B.S. in biological sciences and biotechnology from Tsinghua University.